Home › NCT05289063
Vascular Endothelial Dysfunction in Sleep Apnea
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Aged ≥18 years * Newly diagnosed with obstructive sleep apnea (OSA) who were never treated with CPAP. OSA is defined as apnea-hypopnea index (AHI) ≥5 events/hour of sleep. Exclusion Criteria: * A history of coronary artery disease, heart failure, stroke, diabetes, malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain/fatigue, smoking within the past 5 years * Regular use of any medications
About the study
This double-blind placebo-controlled parallel group randomized study design will be used to test whether 4 weeks of atorvastatin 10 mg daily reduces levels of inflammatory markers in OSA patients treated with CPAP (standard of care). The purpose of this study is to investigate: 1) whether statins reduce endothelial inflammation and pro-thrombotic conditions in OSA, including in patients adherent to CPAP (Aim 1); and 2) whether statins reduce endothelial inflammation and pro-thrombotic conditions by improving endothelial cholesterol metabolism and trafficking in OSA (Aim 2).
What is being tested
- Atorvastatin 10mg (drug)
- Placebo (drug)
- Continuous Positive Airway Pressure Therapy (other)
Sponsor: Columbia University · Participants: 110 · Started: Oct 3, 2022
Contact the study team
- Sanja Jelic, MD · Phone: 2125438875
Official record on ClinicalTrials.gov — NCT05289063
Locations in the U.S.
| New York | Columbia University Irving Medical Center, New York |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.